NasdaqGM:CMRX

Stock Analysis Report

Executive Summary

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States.

Snowflake

Fundamentals

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Chimerix's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CMRX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

11.2%

CMRX

1.1%

US Biotechs

0.9%

US Market


1 Year Return

-40.0%

CMRX

9.1%

US Biotechs

15.5%

US Market

Return vs Industry: CMRX underperformed the US Biotechs industry which returned 9.1% over the past year.

Return vs Market: CMRX underperformed the US Market which returned 15.5% over the past year.


Shareholder returns

CMRXIndustryMarket
7 Day11.2%1.1%0.9%
30 Day36.6%10.4%4.7%
90 Day-17.8%5.8%6.6%
1 Year-40.0%-40.0%10.1%9.1%18.1%15.5%
3 Year-61.2%-61.2%16.0%12.3%48.0%38.5%
5 Year-94.3%-94.3%4.5%-0.4%62.1%44.2%

Price Volatility Vs. Market

How volatile is Chimerix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Chimerix undervalued compared to its fair value and its price relative to the market?

1.09x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CMRX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CMRX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CMRX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: CMRX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CMRX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CMRX is good value based on its PB Ratio (1.1x) compared to the US Biotechs industry average (2.8x).


Next Steps

Future Growth

How is Chimerix forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

16.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CMRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CMRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CMRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CMRX's revenue (38.1% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: CMRX's revenue (38.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CMRX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Chimerix performed over the past 5 years?

0.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CMRX has large one-off items impacting its financial results.

Growing Profit Margin: CMRX's current net profit margins (-1168.3%) are higher than last year (-1757.8%).


Past Earnings Growth Analysis

Earnings Trend: CMRX is unprofitable, but has reduced losses over the past 5 years at a rate of 0.4% per year.

Accelerating Growth: Unable to compare CMRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CMRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (86.5%).


Return on Equity

High ROE: CMRX has a negative Return on Equity (-110.79%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Chimerix's financial position?


Financial Position Analysis

Short Term Liabilities: CMRX's short term assets ($126.0M) exceeds its short term liabilities ($15.4M)

Long Term Liabilities: CMRX's short term assets ($126.0M) exceeds its long term liabilities (369.0K)


Debt to Equity History and Analysis

Debt Level: CMRX is debt free.

Reducing Debt: CMRX has no debt compared to 5 years ago when its debt to equity ratio was 3.2%.


Balance Sheet

Inventory Level: CMRX has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if CMRX's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CMRX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CMRX has sufficient cash runway for 1.211917 years if free cash flow continues to grow at historical rates of 2.8% each year.


Next Steps

Dividend

What is Chimerix's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate CMRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CMRX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CMRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CMRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CMRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Chimerix's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average management tenure


CEO

Mike Sherman (53yo)

0.6yrs

Tenure

0

Mr. Michael A. Sherman, also known as Mike, has been Chief Executive Officer of Chimerix, Inc. since April 8, 2019 and serves as President and Director since April 2019. Mr. Sherman served as the Chief Exe ...


Management Age and Tenure

2.8yrs

Average Tenure

49yo

Average Age

Experienced Management: CMRX's management team is considered experienced (2.8 years average tenure).


Board Age and Tenure

1.7yrs

Average Tenure

67yo

Average Age

Experienced Board: CMRX's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: CMRX insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$87,75713 Nov 19
Fred Middleton
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares50,000
Max PriceUS$1.82
BuyUS$156,00007 Nov 19
Michael Andriole
EntityIndividual
Role
Chief Financial Officer
Chief Business Officer & CFO
Shares100,000
Max PriceUS$1.56
BuyUS$15,79706 Nov 19
Robert Meyer
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares10,000
Max PriceUS$1.58
BuyUS$64,80029 May 19
Martha Demski
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares18,000
Max PriceUS$3.60
BuyUS$104,31620 May 19
Michael Sherman
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares30,000
Max PriceUS$3.48
BuyUS$87,67813 May 19
Fred Middleton
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares30,000
Max PriceUS$2.92

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.6%.


Management Team

  • Mike Sherman (53yo)

    CEO, President & Director

    • Tenure: 0.6yrs
  • Michelle LaSpaluto

    Executive Director of Financial Planning

    • Tenure: 3.8yrs
  • Michael Alrutz (49yo)

    Senior VP

    • Tenure: 5.2yrs
  • William Nichols (50yo)

    Chief Medical Officer

    • Tenure: 5.2yrs
    • Compensation: US$1.00m
  • Randall Lanier

    Chief Science Officer

    • Tenure: 2.8yrs
  • Roy Ware

    Chief Manufacturing & Technology Officer

    • Tenure: 2.8yrs
  • Mike Andriole (46yo)

    Chief Business Officer & CFO

    • Tenure: 0.5yrs
  • David Jakeman (42yo)

    Executive Director of Finance & Accounting and Principal Accounting Officer

    • Tenure: 0.4yrs

Board Members

  • Fred Middleton (70yo)

    Independent Director

    • Tenure: 1.7yrs
    • Compensation: US$272.50k
  • Seth Rudnick (70yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Martha Demski (66yo)

    Chairman of the Board

    • Tenure: 1.4yrs
    • Compensation: US$134.53k
  • Mike Sherman (53yo)

    CEO, President & Director

    • Tenure: 0.6yrs
  • Douglas Richman

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Michael Boeckh

    Member of Clinical Advisory Board

    • Tenure: 0yrs
  • Earl Kern

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Raymund Razonable

    Member of Clinical Advisory Board

    • Tenure: 0yrs
  • Robert Meyer (60yo)

    Independent Director

    • Tenure: 1.7yrs
    • Compensation: US$265.93k
  • Edward Greissing (68yo)

    Independent Director

    • Tenure: 1.7yrs
    • Compensation: US$267.25k

Company Information

Chimerix, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Chimerix, Inc.
  • Ticker: CMRX
  • Exchange: NasdaqGM
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$121.537m
  • Shares outstanding: 61.38m
  • Website: https://www.chimerix.com

Number of Employees


Location

  • Chimerix, Inc.
  • 2505 Meridian Parkway
  • Suite 100
  • Durham
  • North Carolina
  • 27713
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CMRXNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDApr 2013
CXFDB (Deutsche Boerse AG)YesCommon StockDEEURApr 2013

Biography

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company’s lead product candidate is brincidofovir,  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/19 00:41
End of Day Share Price2019/11/18 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.